Upcoming events

  • Jan Jezek, Chief Scientific Officer, speaking at The 17th Annual Peptide Therapeutics Symposium

    21st October 2022 - 22nd October 2022

Latest News

  • 20th September 2022

    ARECOR PRESENTS DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 AT EASD

  • 9th August 2022

    ARECOR GRANTED EUROPEAN PATENTS PROTECTING PROPRIETARY FORMULATIONS OF HIGH CONCENTRATION HUMIRA® BIOSIMILAR

  • 4th July 2022

    ARECOR ANNOUNCES PRESENTATION AT EASD 2022 OF PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES

News

Reset
  • 20/09/2022

    ARECOR PRESENTS DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 AT EASD

  • 09/08/2022

    ARECOR GRANTED EUROPEAN PATENTS PROTECTING PROPRIETARY FORMULATIONS OF HIGH CONCENTRATION HUMIRA® BIOSIMILAR

  • 04/07/2022

    ARECOR ANNOUNCES PRESENTATION AT EASD 2022 OF PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES

  • 16/06/2022

    ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH A TOP 5 GLOBAL PHARMACEUTICAL COMPANY

  • 18/05/2022

    ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE

  • 28/04/2022

    ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING

  • 12/04/2022

    ARECOR ANNOUNCES ORAL PRESENTATION AT ATTD 2022 OF PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING, INSULIN FOR DIABETES

  • 28/03/2022

    ARECOR WINS INNOVATION IN BUSINESS AND BUSINESS PERSON OF THE YEAR AWARDS AT THE CAMBRIDGESHIRELIVE BUSINESS AWARDS

  • 23/03/2022

    ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS

  • 20/01/2022

    ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP